FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average bur	den
	0.5

hours per response: 0.5	Estimated average burden	
	hours per response:	0.5

1. Nume and Address of Reporting Leson			2. Issuer Name and Ticker or Trading Symbol Clearside Biomedical, Inc. [CLSD]		tionship of Reporting F all applicable) Director	n(s) to Issuer 10% Owner	
						21	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 10/03/2017		Officer (give title below)		Other (specify below)
C/O CLEARSID	E BIOMEDICAL	, INC.	10/03/2017				
900 NORTH PO	INT PARKWAY, S	SUITE 200					
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Joint/Group F	iling (Check Applicable
(Street)				X	Form filed by One R	eport	ing Person
ALPHARETTA	GA	30005			Form filed by More t Person	han C	One Reporting
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1- Non-Derivative Securities Acquired, Disposed 01, 01 Denenciary Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V Amount (A) or Price		Price	Transaction(s) (Instr. 3 and 4)	(1150.4)			
Common Stock	10/03/2017		S ⁽¹⁾		15,000 ⁽²⁾	D	\$8.64 ⁽³⁾	3,856,394	Ι	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock	10/04/2017		S ⁽¹⁾		14,000(6)	D	\$8.59 ⁽⁷⁾	3,842,394	Ι	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock	10/05/2017		S ⁽¹⁾		6,000 ⁽⁸⁾	D	\$8.3 4 ⁽⁹⁾	3,836,394	Ι	See Footnotes ⁽⁴⁾⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(e.g., puis, cails, waitants, opti								options, t	Jonventin	10 300	Junitesj				
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	ative rities ired osed	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on June 12, 2017.

2. Consists of (i) 441 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 5,752 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 522 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 930 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 7,355 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").

3. This transaction was executed in multiple trades at prices ranging from \$8.37 to \$9.09, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

4. The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVP IV SBIC, HVP IV and Hatteras NC.

5. The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

6. Consists of (i) 412 shares sold by HATEras NC, (ii) 5,369 shares sold by HVP III, (iii) 487 shares sold by HVA III, (iv) 868 shares sold by HVP IV and (v) 6,864 shares sold by HVP IV SBIC.

7. This transaction was executed in multiple trades at prices ranging from \$8.33 to \$8.975, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

8. Consists of (i) 176 shares sold by Hatteras NC, (ii) 2,301 shares sold by HVP III, (iii) 209 shares sold by HVA III, (iv) 372 shares sold by HVP IV and (v) 2,942 shares sold by HVP IV SBIC.

9. This transaction was executed in multiple trades at prices ranging from \$8.05 to \$8.46, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Remarks:

/s/ Brian F. Leaf, Attorney-in-10/05/2017

Fact for Clay Thorp

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.